RARE DISEASE DAY 2025 The Neurenati Team is dedicated to develop a novel therapy for newborns affected by Hirschsprung disease (HD). NEU-001 is a combination therapy, composed of a neurotrophic growth factor, with strong intent of regenerating enteric nervous system in HD newborns.
Neurenati Therapeutics
生物技术研究
Hirschsprung disease (HSCR) is a deadly birth defect affecting 1/5000 children.
关于我们
Neurenati develops novel therapies for GI rare diseases
- 网站
-
www.neurenati.com
Neurenati Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 类型
- 私人持股
- 创立
- 2020